About
MAIA Biotech
MAIA.US
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Profile
- Company Name
- MAIA Biotechnology, Inc.
- Market
- NYSEAM
- Founded
- Industry
- --
- Fiscal Year End
- December 31
- Website
- maiabiotech.com